Pricing Log in Create free account
Friday 6 November 2026 Export LEXX’s income statement to Excel — free account

Lexaria Bioscience Corp.

LEXX Healthcare Biotechnology

Lexaria Bioscience Corp.’s revenue for fiscal 2025 (year ended August 2025) was $705,900.00, up 52.0% from fiscal 2024.

Revenue
−89.1%
EPS
+61.9%
Free cash flow
+53.9%

Quarter to May 2026, against a year earlier

4.42 0.25 +6.00%
Market cap
$8.8M
P/E
0.0×
Fwd P/E
−0.9×
Dividend yield
—
F-score
4/9
Altman Z
−23.88
Beneish M
−3.56
Dividend safety
n/a
Overview
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios

Insider Decisions last twelve months

Trades a month
Jan 26 Apr 26 Jul 26 Oct 26
Buy — — — — — — — — — — — —
Sell — — — — — — — — — — — —
Insider Ownership 0.00%

Capital & Financial Ratios $m

Size
Market Cap 8.78
Revenue ttm 0.54
Net income ttm (7.74)
Free cash flow ttm (7.53)
Net debt Q (3.62)
Valuation
P/E 0.00
Forward P/E (0.86) (negative: loss-making)
Price / sales 12.64 (above 10: high)
Forward P/S Powerpack
Price / FCF 0.00
Price / book 1.58
Financial health
Current ratio Q 10.60 (at or above 1.5: strong)
Debt / equity Q 0.00 (at or below 0.5: strong)
Interest coverage Q (122.25)
Growth
Revenue growth Q −89.12% (below 0%: shrinking)
Operating income growth Q +46.84% (above 0%: growing)
EPS, this year +59.09% (at or above 15%: strong)
EPS, next year A −14.81% (below 0%: weak)
Revenue, next year A −97.17% (below 0%: weak)
EPS, past 5 yrs —
EPS, next 5 yrs A +24.86% (at or above 15%: strong)

Green and red mark values outside typical ranges; (Q) is the latest quarter, (A) analysts’ estimates. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 6.1×, against a ten-year median of 41.5×; over the ten years it ranged from 3.1× in 2026 to 454× in 2018.
P/S against its own 10 years 1.92%
10-year low 10-year high
P/B against its own 10 years 6.50%
10-year low 10-year high
EV/Sales against its own 10 years 4.12%
10-year low 10-year high

Dividends

Yield
—
Annual rate
—
Payout ratio
—

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 1 7 2 4
Receivables 0 0 0 0
Inventory — — — —
Other — — — —
2 8 3 4
2023 2024 2025 Q'26
Payables 0 1 1 0
ST’ Debt — — — —
Other — — — —
0 1 1 0

Compound Annual Growth %

10y 5y 3y
Sales — 17.53% 40.34%
Cash Flow — 0.00% 0.00%
Earnings — 0.00% 0.00%
Book Value — 0.95% (30.14%)

Earnings Trends EPS, adjusted, against the consensus

Q3 FY26 Estimate −0.90 Actual −1.20

Earnings per share against the consensus, by quarter
Quarter Estimate Reported Result
Q4 FY25 −2.40 −1.95 Beat by 0.45
Q1 FY26 −1.95 −1.05 Beat by 0.90
Q2 FY26 −1.50 −0.90 Beat by 0.60
Q3 FY26 −0.90 −1.20 Miss by 0.30
Q4 FY26 −0.90 — Reports 25 November 2026

EPS $

Nov Feb May Aug Year
’26 (1.05) (0.90) (1.20) — —
’25 (2.40) (2.25) (3.15) (2.07) (9.90)
’24 (1.95) (0.90) (1.95) (2.06) (7.05)
’23 (4.50) (3.30) (5.55) (2.29) (15.14)
’22 (5.25) (3.75) (6.15) (3.60) (18.59)
’21 (3.60) 1.35 (7.50) (4.66) (14.39)
’20 (5.26) (5.62) (7.53) (4.50) (22.51)
Fiscal quarters ending in the months shown.

Revenue $m

Nov Feb May Aug Year
’26 — 0 — — —
’25 0 0 0 0 1
’24 0 0 0 0 0
’23 0 0 0 0 0
’22 0 0 0 0 0
’21 0 0 0 0 1
’20 0 0 0 0 0
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Nov Feb May Aug Year
’26 (1) (2) (2) — —
’25 (3) (1) (4) (3) (10)
’24 (1) (1) (1) (2) (5)
’23 (1) (1) (2) (2) (6)
’22 (1) (1) (1) (1) (5)
’21 (1) (1) (1) (1) (4)
’20 (1) (1) (1) (1) (3)
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Nov Feb May Aug Year
’26 (1) (2) (2) — —
’25 (3) (2) (4) (3) (11)
’24 (1) (1) (1) (2) (5)
’23 (1) (1) (2) (2) (6)
’22 (1) (1) (1) (1) (5)
’21 (1) (1) (1) (1) (4)
’20 (1) (1) (1) (1) (3)
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

1
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to August

Ten-year view Analyst estimates Powerpack
Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 TTM May ’26 Trend 10 yrs 2026e 2027e 2028e Next 3/yr
Income, $m
Income, $m Revenue 0 0 0 0 0 1 0 0 0 1 1 +37.3% 0 1 2 +30.9%
Gross margin, % (13.51) 50.94 94.18 89.71 68.42 75.74 71.89 86.07 98.97 99.62 100.00 +113.1 pt
EBT (1) (2) (7) (4) (4) (4) (7) (7) (6) (12) (8) +28.2%
EBT margin, % (3,138.08) (3,033.81) (1,525.32) (1,868.10) (1,317.92) (576.19) (2,891.03) (2,967.51) (1,251.07) (1,687.41) 0.00 +1,450.7 pt
Net income (1) 0 (7) (4) (4) (4) (7) (7) (6) (12) (8) +28.9%
Per share, $
Per share, $ Revenue 0.42 0.49 2.75 1.29 1.70 2.47 0.65 0.51 0.56 0.59 0.00 +3.9%
Earnings (12.47) (14.31) (41.93) (24.07) (22.51) (14.39) (18.59) (15.14) (7.05) (9.90) (5.22) (2.5%)
Cash flow (6.78) (10.01) (15.98) (17.39) (14.16) (13.62) (12.43) (13.33) (6.00) (8.70) (4.49) +2.8%
Capex 0.00 0.00 (0.54) (4.45) (0.18) 0.66 (0.46) (0.38) (0.23) (0.08) (0.06) n/m
Free cash flow (6.78) (10.01) (16.52) (21.84) (14.34) (12.96) (12.89) (13.71) (6.23) (8.79) (4.55) +2.9%
Book value 2.73 23.02 15.15 14.41 13.42 44.60 19.45 6.07 9.27 2.17 2.63 (2.5%)
Shares, m 0 0 0 0 0 0 0 0 1 1 1 +32.2%
Valuation, ×
Valuation, × P/E 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.0
P/S 0.00 0.00 335.55 227.72 91.50 37.81 68.21 30.73 97.40 22.60 12.64 91.2
P/B 0.00 7.66 60.88 20.34 11.60 2.09 2.28 2.59 5.90 6.13 1.58 11.9
EV/Sales 0.00 0.00 331.54 221.65 87.54 21.60 44.38 24.48 83.42 19.90 6.08 83.5
EV/FCF 0.00 0.00 (55.18) (13.06) (8.35) (4.10) (2.24) (0.91) (7.50) (1.33) (0.44) (9.3)
Cash, $m
Cash, $m Operating cash flow (1) (1) (3) (3) (3) (4) (5) (6) (5) (10) (7) +35.9%
Capex 0 0 0 (1) 0 0 0 0 0 0 0 +19.5%
Free cash flow (1) (1) (3) (4) (3) (4) (5) (6) (5) (11) (8) +36.0%
Balance, $m
Balance, $m Working capital 0 3 2 2 2 12 7 2 7 2 4 +43.5%
Net debt 0 (2) (2) (1) (1) (12) (6) (1) (7) (2) (4) n/m
Shareholders’ equity 0 3 2 2 2 13 8 3 8 3 4 +28.8%
Returns, %
Returns, % ROA (70.90) (659.83) (440.85) (162.85) (142.97) (50.04) (68.90) (122.09) (96.98) (182.50) (134.20) (111.6) pt
ROIC 0.00 0.00 (568.66) (156.74) (209.81) (269.29) (281.06) (339.63) (325.87) (1,168.81) (662.56) (1,168.8) pt
ROE (74.25) (114.25) (245.03) (170.46) (158.21) (51.81) (70.25) (129.26) (112.10) (231.96) (162.60) (157.7) pt
People
People Employees — — — 8 4 6 7 5 7 7 — (2.2%)
Revenue/emp, $m 0.00 0.00 0.00 0.03 0.08 0.12 0.04 0.05 0.07 0.10 — n/m
Negative figures in brackets.
estimates

All 10 years →

Fiscal years to Aug 2025 · latest quarter Feb 2026 · fundamentals updated 26 Oct 2026

Lexaria Bioscience Corp. vs peers in Biotechnology (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
ACTU Actuate Therapeutics, Inc. $18.0M — (loss-making) — — n/m −5.54% (below 0%: shrinking) — 0.00% Compare
MBRX Moleculin Biotech, Inc. $9.2M 0.0× — — n/m −19.26% (below 0%: shrinking) 0.00% 0.00% Compare
CMMB Chemomab Therapeutics Ltd. Sponsored ADR $9.1M — (loss-making) — — n/m +47.89% (above 0%: growing) 0.00% 0.00% Compare
LEXX Lexaria Bioscience Corp. $8.8M — (loss-making) — (loss-making) −89.12% (below 0%: shrinking) n/m +53.90% (above 0%: growing) 100.00% 0.00%
NKGN NKGen Biotech, Inc. $8.8M — (loss-making) — — n/m +28.68% (above 0%: growing) 100.00% 0.00% Compare
LTRN Lantern Pharma Inc. $7.9M — (loss-making) — — n/m +25.31% (above 0%: growing) 0.00% 0.00% Compare
TOVX Theriva Biologics, Inc. $7.7M — (loss-making) — +33.08% (above 0%: growing) n/m +34.69% (above 0%: growing) 100.00% 0.00% Compare
VTGN VistaGen Therapeutics, Inc. $7.3M — (loss-making) — (loss-making) +504.92% (above 0%: growing) n/m +22.23% (above 0%: growing) 100.00% (904.34%) Compare
MTVA MetaVia Inc. $7.2M — (loss-making) — — n/m −22.42% (below 0%: shrinking) — 0.00% Compare
Median of peers $8.4M — — — — +23.77% 50.00% 0.00%

All 621 Biotechnology stocks →

Pay and ownership Proxy statement filed 10 December 2025

Chief executive’s pay

Year Total pay Actually paid $100 invested
2025 893.30k 496.75k (77,490.00)
2024 1.40m 1.67m 272,380.00
2023 287.63k 156.94k (64,530.00)

Ownership

Directors and executive officers, together 8.39%
Total pay is as the Summary Compensation Table states it; actually paid revalues the year’s share awards at its end, as the SEC’s pay-versus-performance rule asks. $100 invested is what $100 in the company’s shares at the start of the earliest year shown was worth at each year’s end. Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more. Read the proxy statement

Lexaria Bioscience Corp. (LEXX) Latest News

28 Oct

Impact 4 · · ACCESS Newswire

21 Oct

Impact 4 · · ACCESS Newswire

15 Oct

Impact 4 · · ACCESS Newswire

6 Oct

Impact 4 · · ACCESS Newswire

8 Sep

Impact 4 ·
Impact 3 ·

24 Aug

Impact 4 ·

17 Jul

Impact 3 ·

6 Jul

Impact 3 ·

25 Jun

Impact 3 · · ACCESS Newswire

17 Jun

Impact 3 ·

15 Jun

Impact 3 ·

9 Jun

Impact 3 · · ACCESS Newswire

5 May

Impact 3 · · ACCESS Newswire

29 Apr

Impact 3 · · ACCESS Newswire

23 Apr

Impact 4 · · ACCESS Newswire

21 Apr

Impact 5 ·

15 Apr

Impact 3 ·
Impact 3 · · Simply Wall St.

7 Apr

Impact 3 · · ACCESS Newswire

1 Apr

Impact 4 · · ACCESS Newswire

26 Mar

Impact 4 · · ACCESS Newswire

24 Mar

Impact 4 · · ACCESS Newswire

4 Mar

Impact 3 · · ACCESS Newswire

10 Feb

Impact 3 · · Zacks Small Cap Research

5 Feb

Impact 4 · · ACCESS Newswire

22 Jan

Impact 4 · · ACCESS Newswire

12 Jan

Impact 4 · · ACCESS Newswire

31 Dec

Impact 4 · · TipRanks

30 Dec

Impact 4 · · ACCESS Newswire
stockrow.com/LEXX · Data as of Oct 26, 2026 · For information only; not investment advice. · © 2026 stockrow.com